Is Fidelity High Dividend ETF a Good Investment Now?
Fidelity’s High Dividend ETF (FDVV) is a fund that offers…
Sell
38
PTGX Quote, Financials, Valuation and Earnings
Last price:
$44.44
Seasonality move
:
25.54%
Day range:
$43.93 - $46.45
52-week range:
$24.22 - $60.60
Dividend yield:
0%
P/E ratio:
10.58x
P/S ratio:
6.47x
P/B ratio:
4.04x
Volume:
1.7M
Avg. volume:
1.5M
1-year change:
60.72%
Market cap:
$2.7B
Revenue:
$434.4M
EPS (TTM):
$4.20
Analysts' Opinion
-
Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $69.10, Protagonist Therapeutics has an estimated upside of 55.49% from its current price of $44.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $45.00 representing -1.26% downside risk from its current price of $44.44.
Fair Value
-
According to the consensus of 6 analysts, Protagonist Therapeutics has 55.49% upside to fair value with a price target of $69.10 per share.
PTGX vs. S&P 500
-
Over the past 5 trading days, Protagonist Therapeutics has underperformed the S&P 500 by -0% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Protagonist Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Protagonist Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Protagonist Therapeutics reported revenues of $170.6M.
Earnings Growth
-
Protagonist Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Protagonist Therapeutics reported earnings per share of $1.98.
Enterprise value:
2.3B
EV / Invested capital:
--
Price / LTM sales:
6.47x
EV / EBIT:
9.13x
EV / Revenue:
5.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
12.63x
Price / Operating cash flow:
15.39x
Enterprise value / EBITDA:
9.03x
Gross Profit (TTM):
--
Return On Assets:
46.64%
Net Income Margin (TTM):
63.34%
Return On Equity:
52.01%
Return On Invested Capital:
52.01%
Operating Margin:
74.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $434.4M | $60M | $170.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$131.4M | -$93.7M | $252.8M | $23M | $126.8M | |
| EBITDA | -$128M | -$90.3M | $255.7M | $23.9M | $127.3M | |
| Diluted EPS | -$2.60 | -$1.49 | $4.20 | $0.44 | $1.98 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $315.6M | $340.7M | $243.1M | $355.6M | $591.6M | |
| Total Assets | $324.5M | $347.7M | $247.9M | $358M | $744.7M | |
| Current Liabilities | $40.2M | $44M | $31.2M | $21.3M | $47.4M | |
| Total Liabilities | $44.9M | $47.7M | $32.3M | $21.3M | $69.4M | |
| Total Equity | $279.6M | $300M | $215.6M | $336.7M | $675.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$108.1M | -$70.2M | $184.2M | $17M | -$29.2M | |
| Cash From Investing | $91.5M | -$39.3M | -$299.5M | -$61.3M | -$8.7M | |
| Cash From Financing | $18.8M | $170.5M | $25.9M | $527K | $4M | |
| Free Cash Flow | -$108.9M | -$70.8M | $182.8M | $16.9M | -$29.5M | |
PTGX
Sector
Market Cap
$2.7B
$35.3M
Price % of 52-Week High
73.33%
41.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
60.72%
-44.25%
Beta (5-Year)
2.305
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$47.78
200-day SMA
Buy
Level
$41.48
Bollinger Bands (100)
Buy
Level
36.49 - 47.55
Chaikin Money Flow
Buy
Level
64.5M
20-day SMA
Sell
Level
$50.94
Relative Strength Index (RSI14)
Sell
Level
41.74
ADX Line
Sell
Level
24.97
Williams %R
Buy
Level
-95.1977
50-day SMA
Buy
Level
$43.12
MACD (12, 26)
Buy
Level
0.90
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
141.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (22.3002)
Buy
CA Score
(Annual)
Level (3.8295)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-12.0005)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Stock Forecast FAQ
In the current month, PTGX has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The PTGX average analyst price target in the past 3 months is $69.10.
-
Where Will Protagonist Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Protagonist Therapeutics share price will rise to $69.10 per share over the next 12 months.
-
What Do Analysts Say About Protagonist Therapeutics?
Analysts are divided on their view about Protagonist Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Protagonist Therapeutics is a Sell and believe this share price will drop from its current level to $45.00.
-
What Is Protagonist Therapeutics's Price Target?
The price target for Protagonist Therapeutics over the next 1-year time period is forecast to be $69.10 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PTGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Protagonist Therapeutics is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTGX?
You can purchase shares of Protagonist Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Protagonist Therapeutics shares.
-
What Is The Protagonist Therapeutics Share Price Today?
Protagonist Therapeutics was last trading at $44.44 per share. This represents the most recent stock quote for Protagonist Therapeutics. Yesterday, Protagonist Therapeutics closed at $44.44 per share.
-
How To Buy Protagonist Therapeutics Stock Online?
In order to purchase Protagonist Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kinder Morgan Dividend Yield Worth It?
Kinder Morgan (NYSE:KMI) is a major energy infrastructure company in…
What Is the Best ETF to Buy This Year?
The stock market has gotten off to an extremely rough…
Stock Ideas
Sell
37
Is AAPL Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
31
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 32x
Alerts
Sell
45
RGC alert for Apr 5
Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.
Sell
25
GDXU alert for Apr 5
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.
Buy
76
SOXS alert for Apr 5
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.
